Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 10/20 | 0.49 |
| ▸ | MMP9 | P14780 | 7/20 | 0.49 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 3/20 | 0.45 |
| ▸ | MMP3 | P08254 | 3/20 | 0.45 |
| ▸ | MMP7 | P09237 | 3/20 | 0.45 |
| ▸ | MMP13 | P45452 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14115850 | 1.00 | TDP1 (0.50) | TDP1MMP2MMP9F2ADAMTS4 | |
| SCHEMBL14045372 | 0.91 | MMP13 (0.49) | TDP1MMP2MMP9F2ADAMTS4 | |
| SCHEMBL4597080 | 0.91 | MMP13 (0.49) | TDP1MMP2MMP9F2ADAMTS4 | |
| SCHEMBL4597319 | 0.91 | NPSR1 (0.56) | TDP1MMP2MMP9F2ADAMTS4 | |
| SCHEMBL14045373 | 0.91 | NPSR1 (0.56) | TDP1MMP2MMP9F2ADAMTS4 | |
| SCHEMBL5329575 | 0.90 | TDP1 (0.52) | TDP1MMP2MMP9F2ADAMTS4 | |
| SCHEMBL14565793 | 0.88 | TDP1 (0.47) | TDP1MMP2MMP9F2ADAMTS4 | |
| SCHEMBL4608465 | 0.88 | TDP1 (0.50) | TDP1MMP2MMP9F2ADAMTS4 | |
| SCHEMBL14115849 | 0.88 | TDP1 (0.50) | TDP1MMP2MMP9F2ADAMTS4 | |
| SCHEMBL4597815 | 0.85 | TDP1 (0.57) | TDP1MMP2MMP9F2ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2008-07-24 | — | — | US | claimed |
| US-7399786-B2 | Derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | claimed |
| EP-1907352-A2 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | Bexel Pharmaceuticals Inc (US) | 2008-04-09 | — | — | EP | claimed |
| WO-2007005774-A9 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS INC (US) | 2007-03-08 | — | — | WO | claimed |
| WO-2007005774-A2 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | WO | claimed |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | claimed |
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2008-07-24 | — | — | US | disclosed |
| US-7399786-B2 | Derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1907352-A2 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | Bexel Pharmaceuticals Inc (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007005774-A9 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS INC (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007005774-A2 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | GPR119, AADAT, FABP4 | TDP1 3135/4885MMP2 3450/4885MMP9 4643/4885 |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | GPR119, AADAT, FABP4 | TDP1 3135/4885MMP2 3450/4885MMP9 4643/4885 |
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | GPR119, AADAT, FABP4 | TDP1 3135/4885MMP2 3450/4885MMP9 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.